Tonix Pharmaceuticals Holding (TNXP) Stock

$12.85 1.61 (14.32%)
Market Cap: $71.84M | NASDAQ

Tonix Pharmaceuticals Holding Chart


Company Profile

Price: $12.85

Market Cap: $71.84M

Exchange: NASDAQ

CEO: Dr. Seth Lederman M.D.

Sector: Healthcare

Industry: Biotechnology

Employees: -0.00B

Headquarters: Chatham, NJ

Business Summary

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Tonix Pharmaceuticals Holding News

Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash

Company had $98.8 million in cash as of December 31, 2024; existing cash expected to fund planned operations into the first quarter of 2026

News image

Tonix Pharmaceuticals Announces Positive Topline Results from Phase 1 Trial for TNX-1500, a Next Generation anti-CD40L mAb Candidate for Prevention of Kidney Transplant Rejection and Treatment of Autoimmune Diseases

Results from the Phase 1 single ascending dose study support proceeding to develop a Phase 2 trial for the prevention of kidney transplant rejection

News image

Tonix Pharmaceuticals to Participate in the 2025 BIO CEO & Investor Conference

CHATHAM, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present at the BIO CEO & Investor Conference on February 10, 2025, at 1:45 p.m. ET in New York City.

News image

Tonix Pharmaceuticals Promotes Siobhan Fogarty to Chief Technical Officer

Ms. Fogarty has served at Tonix since 2016, most recently as Executive Vice President, Product Development Tonix is Preparing for Potential Launch of TNX-102 SL for the management of fibromyalgia with U.S. FDA PDUFA goal date of August 15, 2025 CHATHAM, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the promotion of Siobhan Fogarty to Chief Technical Officer (CTO), effective immediately.

News image

Tonix Pharmaceuticals Announces 1-for-100 Reverse Stock Split

CHATHAM, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that it will effect a 1-for-100 reverse stock split of its outstanding common stock. The reverse stock split will be effective for trading purposes as of the commencement of trading on February 5, 2025.

News image

Is Tonix Pharmaceuticals the Next Biotech Breakout?

Clinical-stage biopharmaceutical company Tonix Pharmaceuticals NASDAQ: TNXP is gaining significant attention from investors and market participants. The company develops therapies for conditions with high unmet needs, with a focus on pain management, CNS disorders, and public health vaccines.

News image

Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia

Tonix received FDA's Day 74 Letter granting TNX-102 SL a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025

News image

Tonix Pharmaceuticals Announces FDA Acceptance of the New Drug Application (NDA) for TNX-102 SL for Fibromyalgia

FDA is expected to assign a Prescription Drug User Fee Act (PDUFA) target action date and announce whether Priority Review has been granted in the Day 74 Letter

News image

Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights

Submitted New Drug Application (NDA) to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 studies

News image

Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research.

News image

Tonix Pharmaceuticals to Participate in the NobleCon20 Investor Conference

CHATHAM, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present and conduct investor meetings at NobleCon20, Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference, being held December 3-4 in Boca Raton, Fla.

News image

Muscarinic Acetylcholine Receptor M1 Antagonists Pipeline Research Report 2024: Comprehensive Insights on 8+ Drugs Featuring Tonix Pharmaceuticals, BMS, WinSanTor, and Apnimed

Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Muscarinic Acetylcholine Receptor M1 Antagonists - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about 5+ companies and 8+ pipeline drugs in Muscarinic Acetylcholine Receptor M1 Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

News image

Tonix Pharmaceuticals to Present at the Winter 2024 Investor Summit Virtual

CHATHAM, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the Winter 2024 Investor Summit Virtual on Thursday, November 21, 2024, at 10:00 a.m. ET.

News image

Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research.

News image

Tonix Pharmaceuticals Announces Poster Presentation at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting

CHATHAM, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will deliver a poster presentation at the ACR Convergence 2024 Annual Meeting, which will be held in Washington, D.C., November 14-19, 2024. A copy of the Company's presentation will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference. Additional meeting information can be found on the ACR website here.

News image

Tonix Pharmaceuticals Announces Peer-Reviewed Publication in mSphere Journal Highlighting the Tolerability of Company's Single-Dose Mpox and Smallpox Vaccine Candidate TNX-801, in Immune-Compromised Animals

The World Health Organization (WHO) declared the spread of new Clade Ib Mpox a public health emergency of international concern (PHEIC): Second Mpox-related WHO PHEIC declaration in two years

News image

Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024

New data show tolerability and no evidence of spreading to blood or tissues even at high doses of Tonix's attenuated live-virus, minimally replicating vaccine candidate TNX-801 in immunocompromised animals

News image

Tonix Pharmaceuticals to Present at BIO-Europe® 2024

CHATHAM, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at BIO-Europe®, being held November 4-6, 2024, in Stockholm, Sweden. The presentation will take place on Monday, November 4, 2024, at 1:00 p.m. CET.

News image

Tonix Pharmaceuticals to Present at the 2024 ThinkEquity Conference

CHATHAM, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the ThinkEquity Conference on Wednesday, October 30, 2024, at 9:30 a.m. ET, and host investor meetings. The conference is being held at the Mandarin Oriental, New York in New York City.

News image

Tonix Pharmaceuticals Announces Submission of the TNX-102 SL New Drug Application (NDA) for Fibromyalgia to the U.S. Food and Drug Administration (FDA)

NDA based on two Phase 3 studies of TNX-102 SL in fibromyalgia with statistically significant results on the primary endpoint of reducing widespread pain; generally well tolerated

News image

Tonix Pharmaceuticals Announces AI Collaboration with X-Chem to Develop Broad-Spectrum Antivirals

AI (Artificial Intelligence) and ML (Machine Learning) drug discovery collaboration will accelerate the development of small molecules as orally available host-targeted broad-spectrum medical countermeasures

News image

The Rush for Non-Addictive Painkillers to Counter the Opioid Crisis Puts Two Companies Close to FDA Decisions

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research.

News image

Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering the Subcutaneous Delivery of FDA-Approved Zembrace® SymTouch® to Treat Migraines

New patent expected to provide market exclusivity into 2036 Zembrace® SymTouch® (sumatriptan succinate injection) 10mg is indicated for the acute treatment of migraine in adults CHATHAM, N.J., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the United States Patent and Trademark Office issued U.S. Patent No.

News image

Tonix Pharmaceuticals Announces Issuance of U.S. Patent by the United States Patent and Trademark Office Covering the Intranasal Delivery of FDA-Approved Tosymra® to Treat Migraines

New patent expected to expire in 2030 Tosymra® (sumatriptan nasal spray) 10mg is indicated and marketed for the acute treatment of migraine in adults CHATHAM, N.J., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the United States Patent and Trademark Office issued U.S. Patent No.

News image

New Hope for Mpox? How TNX-801 Could Meet the WHO's Vaccine Targets for a Safer, Single-Dose Solution

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research.

News image

Tonix Pharmaceuticals Announces That its Single Dose Mpox Vaccine Candidate TNX-801 Aligns with WHO's Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health Emergency

The World Health Organization (WHO) released its preferred target product profile (TPP) criteria for mpox vaccines at its Mpox Research and Innovation Scientific Conference held August 29-30

News image

Tonix Pharmaceuticals Launches National Awareness Campaign on the Impact of Gastroparesis or Stomach Paralysis on the Absorption of Oral Migraine Medications at PAINWeek

Gastroparesis slows the ability of the stomach to empty into the small intestine and thereby can delay absorption of oral medications into the bloodstream

News image

As Research into Pain Accelerates, a Newly Recognized Type of Pain Comes to the Forefront - Tonix Targets it with FDA-Fast Track-Designated TNX-102 SL

CHATHAM, NJ / ACCESSWIRE / September 4, 2024 / This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research.

News image

Tonix Pharmaceuticals Presented Data from Two Posters on TNX-102 SL for Reduction of Acute Stress Reaction and Prevention of PTSD and One Poster for Wound Healing at the 2024 Military Health System Research Symposium (MHSRS)

Investigator-initiated Phase 2 trial to evaluate TNX-102 SL's potential to reduce severity of acute stress reaction (ASR) and frequency of acute stress disorder (ASD) and posttraumatic stress disorder (PTSD) expected to begin third quarter 2024

News image

Tonix Pharmaceuticals and Bilthoven Biologicals to Collaborate on Advancing Development of Tonix's Mpox Vaccine, TNX-801

World Health Organization declared spread of mpox in multiple African countries a public health emergency of international concern (PHEIC) for the second time in two years

News image

Tonix Pharmaceuticals Holding Earnings

This section highlights Tonix Pharmaceuticals Holding's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.

Next Earnings Date

Date: April 07, 2025
Time: --
Est. EPS: $-179.00
Status: Unconfirmed

Last Earnings Results

Date: November 12, 2024
EPS: $-23.00
Est. EPS: $-203.00
Revenue: $2.82M

Earnings Call Transcripts

Transcript Quarter Year Date Estimated EPS Actual EPS

Financial Statements

Access annual & quarterly financial statements for Tonix Pharmaceuticals Holding, including income statements, balance sheets, and cash flow statements..

Annual Income Statement

Breakdown December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020 December 31, 2019
Revenue $7.77M $- $- $- $-
Cost of Revenue $4.74M $112.09M $92.31M $50.51M $28.83M
Gross Profit $3.03M $-112.09M $-92.31M $-50.51M $-28.83M
Gross Profit Ratio 38.97% 0.00% 0.00% 0.00% 0.00%
Research and Development Expenses $86.66M $81.88M $68.84M $36.16M $18.19M
General and Administrative Expenses $34.75M $30.21M $23.47M $14.35M $10.64M
Selling and Marketing Expenses $- $- $- $- $-
Selling General and Administrative Expenses $34.75M $30.21M $23.47M $14.35M $10.64M
Other Expenses $- $- $- $- $-
Operating Expenses $121.41M $112.09M $92.31M $50.51M $28.83M
Cost and Expenses $126.15M $112.09M $92.31M $50.51M $28.83M
Interest Income $- $1.87M $25.00K $48.00K $210.00K
Interest Expense $- $- $- $- $-
Depreciation and Amortization $4.29M $1.25M $50.00K $27.00K $26.00K
EBITDA $-114.09M $-110.84M $-92.26M $-50.48M $-28.80M
EBITDA Ratio -1468.70% 0.00% 0.00% 0.00% 0.00%
Operating Income $-118.38M $-112.09M $-92.31M $-50.51M $-28.83M
Operating Income Ratio -1523.94% 0.00% 0.00% 0.00% 0.00%
Total Other Income Expenses Net $1.72M $1.87M $25.00K $48.00K $210.00K
Income Before Tax $-116.66M $-110.22M $-92.29M $-50.46M $-28.62M
Income Before Tax Ratio -1501.78% 0.00% 0.00% 0.00% 0.00%
Income Tax Expense $- $4.79M $-75.00K $-75.00K $-236.00K
Net Income $-116.66M $-116.88M $-92.29M $-52.17M $-31.09M
Net Income Ratio -1501.78% 0.00% 0.00% 0.00% 0.00%
EPS $-219.09 $-640.26 $-1620.86 $-3530.04 $0.00
EPS Diluted $-219.09 $-640.26 $-1620.86 $-3530.04 $0.00
Weighted Average Shares Outstanding 532.48K 182.54K 56.94K 14.78K -
Weighted Average Shares Outstanding Diluted 532.48K 182.54K 56.94K 14.78K -
SEC Filing Source Source Source Source Source


Income Statement Charts

Breakdown September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 September 30, 2021 June 30, 2021 March 31, 2021 December 31, 2020 September 30, 2020 June 30, 2020 March 31, 2020 December 31, 2019
Revenue $2.82M $2.21M $2.48M $3.78M $3.99M $- $33.90M $- $- $9.03M $- $- $- $- $- $2.91M $- $- $- $--0.00B
Cost of Revenue $1.55M $3.37M $1.66M $3.86M $2.37M $29.00M $893.00K $836.00K $- $102.00K $63.00K $27.00K $18.54M $23.56M $20.74M $- $12.00M $14.19M $7.30M $-
Gross Profit $1.27M $-1.16M $822.00K $-79.00K $1.61M $-29.00M $33.01M $-836.00K $- $8.93M $-63.00K $-27.00K $-18.54M $-23.56M $-20.74M $2.91M $-12.00M $-14.19M $-7.30M $--0.00B
Gross Profit Ratio 44.90% -52.49% 33.12% -2.09% 40.49% 0.00% 97.37% 0.00% 0.00% 98.87% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 0.00% 0.00% 0.00% 100.00%
Research and Development Expenses $9.11M $9.70M $12.86M $17.12M $21.05M $21.98M $26.51M $24.67M $22.20M $16.58M $18.42M $22.30M $13.08M $18.13M $15.33M $12.10M $8.81M $10.57M $4.68M $5.69M
General and Administrative Expenses $- $7.50M $9.31M $11.62M $8.71M $7.03M $7.39M $8.05M $7.39M $6.76M $8.01M $7.26M $5.45M $5.43M $5.41M $4.93M $3.19M $3.62M $2.62M $3.04M
Selling and Marketing Expenses $- $- $- $-1.49M $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Selling General and Administrative Expenses $7.71M $7.50M $9.31M $10.13M $8.71M $7.03M $7.39M $8.05M $7.39M $6.76M $8.01M $7.26M $5.45M $5.43M $5.41M $4.93M $3.19M $3.62M $2.62M $3.04M
Other Expenses $- $- $-593.00K $- $- $646.00K $897.00K $- $- $- $- $29.48M $- $- $- $- $- $- $- $-
Operating Expenses $16.82M $17.20M $22.17M $27.25M $29.76M $29.00M $33.90M $32.73M $29.59M $23.34M $26.44M $29.56M $18.54M $23.56M $20.74M $17.02M $12.00M $14.19M $7.30M $8.73M
Cost and Expenses $18.38M $20.57M $23.83M $31.11M $32.14M $29.00M $33.90M $32.73M $29.59M $23.34M $26.44M $29.56M $18.54M $23.56M $20.74M $17.02M $12.00M $14.19M $7.30M $8.73M
Interest Income $- $- $- $- $172.00K $646.00K $897.00K $1.05M $610.00K $196.00K $19.00K $7.00K $7.00K $9.00K $83.00K $2.00K $9.00K $13.00K $24.00K $27.00K
Interest Expense $- $- $- $- $- $- $- $- $- $196.00K $19.00K $- $- $- $- $- $- $- $- $-
Depreciation and Amortization $510.00K $1.21M $1.21M $1.49M $978.00K $900.00K $893.00K $836.00K $252.00K $102.00K $63.00K $27.00K $10.00K $7.00K $6.00K $7.00K $8.00K $6.00K $6.00K $5.00K
EBITDA $-13.38M $-17.39M $-20.38M $-25.83M $-27.00M $-28.08M $-33.01M $-31.89M $-29.34M $-23.23M $-26.37M $-29.45M $-18.52M $-23.55M $-20.73M $-17.02M $-11.99M $-14.19M $-7.29M $-8.73M
EBITDA Ratio -473.99% -787.68% -860.23% -683.73% -705.62% 0.00% -100.00% 0.00% 0.00% -258.51% 0.00% 0.00% 0.00% 0.00% 0.00% -584.18% 0.00% 0.00% 0.00% 1746800.00%
Operating Income $-15.55M $-18.36M $-21.35M $-27.33M $-28.15M $-29.00M $-33.90M $-32.73M $-29.59M $-23.34M $-26.40M $-29.56M $-18.54M $-23.56M $-20.74M $-17.02M $-12.00M $-14.19M $-7.30M $-8.73M
Operating Income Ratio -551.17% -831.48% -860.23% -723.18% -705.62% 0.00% -100.00% 0.00% 0.00% -258.51% 0.00% 0.00% 0.00% 0.00% 0.00% -584.18% 0.00% 0.00% 0.00% 1746800.00%
Total Other Income Expenses Net $1.34M $-60.42M $6.41M $7.00K $172.00K $646.00K $897.00K $1.05M $610.00K $196.00K $19.00K $-74.00K $7.00K $9.00K $83.00K $2.00K $9.00K $13.00K $24.00K $27.00K
Income Before Tax $-14.21M $-78.78M $-14.94M $-27.32M $-27.98M $-28.36M $-33.01M $-31.68M $-28.98M $-23.14M $-26.42M $-29.55M $-18.53M $-23.55M $-20.65M $-17.02M $-11.99M $-14.18M $-7.27M $-8.71M
Income Before Tax Ratio -503.65% -3567.75% -601.89% -723.00% -701.30% 0.00% -97.35% 0.00% 0.00% -256.34% 0.00% 0.00% 0.00% 0.00% 0.00% -584.11% 0.00% 0.00% 0.00% 1741400.00%
Income Tax Expense $- $- $-1.21M $--0.00B $-1.22M $29.00M $-1.79M $5.61M $- $-196.00K $-19.00K $-92.42M $- $- $--0.00B $-7.00K $- $- $- $-5.00K
Net Income $-14.21M $-78.78M $-14.94M $-27.32M $-27.98M $-28.36M $-33.01M $-34.08M $-28.98M $-27.39M $-26.42M $-29.55M $-18.53M $-23.55M $-20.65M $-17.02M $-11.99M $-14.18M $-8.98M $-11.18M
Net Income Ratio -503.65% -3567.75% -601.89% -723.00% -701.30% 0.00% -100.00% 0.00% 0.00% -254.17% 0.00% 0.00% 0.00% 0.00% 0.00% -584.11% 0.00% 0.00% 0.00% 1741400.00%
EPS $-0.23 $-19.28 $-5.91 $-27.53 $-58.40 $-85.71 $-102.85 $-111.06 $-4.24 $-244.55 $-321.28 $-419.18 $-319.96 $-449.35 $-455.62 $-664.75 $-603.27 $0.00 $0.00 $0.00
EPS Diluted $-0.23 $-19.28 $-5.91 $-27.53 $-58.40 $-85.71 $-102.85 $-111.06 $-4.24 $-244.55 $-321.28 $-419.18 $-319.96 $-449.35 $-455.62 $-664.75 $-603.27 $0.00 $0.00 $0.00
Weighted Average Shares Outstanding 62.12M 4.09M 2.53M 992.40K 478.99K 330.85K 320.89K 306.90K 6.84M 112.02K 82.22K 70.50K 57.91K 52.42K 45.33K 25.61K 19.88K - - -
Weighted Average Shares Outstanding Diluted 62.12M 4.09M 2.53M 992.40K 478.99K 330.85K 320.89K 306.90K 6.84M 112.02K 82.22K 70.50K 57.91K 52.42K 45.33K 25.61K 19.88K - - -
SEC Filing Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source

Annual Balance Sheet

Breakdown December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020 December 31, 2019
Cash and Cash Equivalents $24.95M $120.23M $178.66M $77.07M $11.25M
Short Term Investments $- $- $- $- $-
Cash and Short Term Investments $24.95M $120.23M $178.66M $77.07M $11.25M
Net Receivables $4.59M $- $7.73M $7.63M $-
Inventory $14.15M $-8.04M $-7.73M $-7.63M $-1.01M
Other Current Assets $4.08M $10.55M $2.66M $3.29M $1.69M
Total Current Assets $47.77M $130.78M $189.05M $87.99M $13.95M
Property Plant Equipment Net $94.85M $94.53M $51.47M $9.83M $390.00K
Goodwill $965.00K $- $- $- $-
Intangible Assets $9.74M $120.00K $- $120.00K $120.00K
Goodwill and Intangible Assets $10.71M $120.00K $120.00K $120.00K $120.00K
Long Term Investments $- $241.00K $240.00K $240.00K $100.00K
Tax Assets $- $-120.00K $-240.00K $-240.00K $-100.00K
Other Non-Current Assets $1.13M $143.00K $259.00K $245.00K $100.00K
Total Non-Current Assets $106.69M $94.91M $51.85M $10.19M $610.00K
Other Assets $- $- $- $- $-
Total Assets $154.46M $225.69M $240.90M $98.18M $14.56M
Account Payables $3.78M $8.07M $13.28M $4.60M $3.07M
Short Term Debt $2.62M $432.00K $489.00K $595.00K $352.00K
Tax Payables $- $- $- $- $-
Deferred Revenue $2.98M $3.27M $2.83M $2.17M $704.00K
Other Current Liabilities $9.50M $6.41M $5.11M $2.46M $1.01M
Total Current Liabilities $18.88M $18.18M $21.72M $9.82M $5.13M
Long Term Debt $7.19M $328.00K $467.00K $716.00K $6.00K
Deferred Revenue Non-Current $- $- $- $- $-
Deferred Tax Liabilities Non-Current $- $- $- $- $-
Other Non-Current Liabilities $22.86M $- $- $- $-
Total Non-Current Liabilities $30.05M $328.00K $467.00K $716.00K $6.00K
Other Liabilities $- $- $- $- $-
Total Liabilities $48.93M $18.51M $22.18M $10.54M $5.14M
Preferred Stock $- $- $- $- $-
Common Stock $59.00K $76.00K $496.00K $206.00K $9.00K
Retained Earnings $-600.66M $-470.04M $-359.82M $-267.53M $-217.07M
Accumulated Other Comprehensive Income Loss $-232.00K $-167.00K $-92.00K $-62.00K $-46.00K
Other Total Stockholders Equity $706.36M $677.31M $578.61M $355.04M $226.52M
Total Stockholders Equity $105.53M $207.18M $218.72M $87.65M $9.42M
Total Equity $105.53M $207.18M $218.72M $87.65M $9.42M
Total Liabilities and Stockholders Equity $154.46M $225.69M $240.90M $98.18M $14.56M
Minority Interest $- $- $- $- $-
Total Liabilities and Total Equity $154.46M $225.69M $240.90M $98.18M $14.56M
Total Investments $900.00K $241.00K $240.00K $240.00K $100.00K
Total Debt $9.81M $760.00K $956.00K $1.31M $358.00K
Net Debt $-15.13M $-119.47M $-177.70M $-75.76M $-10.89M


Balance Sheet Charts

Breakdown September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 September 30, 2021 June 30, 2021 March 31, 2021 December 31, 2020 September 30, 2020 June 30, 2020 March 31, 2020 December 31, 2019
Cash and Cash Equivalents $28.23M $4.16M $7.05M $24.95M $6.91M $25.62M $71.97M $120.23M $139.98M $145.48M $140.44M $178.66M $182.97M $165.72M $164.21M $77.07M $55.66M $55.02M $30.66M $11.25M
Short Term Investments $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Cash and Short Term Investments $28.23M $4.16M $7.05M $24.95M $6.91M $25.62M $71.97M $120.23M $139.98M $145.48M $140.44M $178.66M $182.97M $165.72M $164.21M $77.07M $55.66M $55.02M $30.66M $11.25M
Net Receivables $4.01M $3.34M $- $4.59M $1.56M $- $- $- $- $- $- $7.73M $- $- $- $7.63M $- $- $- $-
Inventory $7.93M $9.46M $12.35M $14.15M $13.32M $13.70M $- $-8.04M $- $- $- $-7.73M $- $- $- $-7.63M $- $- $- $-1.01M
Other Current Assets $10.37M $8.34M $10.70M $2.57M $9.54M $12.01M $11.75M $10.55M $22.32M $46.27M $25.11M $2.66M $12.11M $11.55M $8.95M $3.29M $6.36M $2.60M $2.73M $1.69M
Total Current Assets $50.54M $25.29M $30.10M $47.77M $31.34M $51.33M $83.73M $130.78M $151.14M $191.75M $152.99M $189.05M $195.08M $177.27M $173.16M $87.99M $62.02M $57.63M $33.40M $13.95M
Property Plant Equipment Net $43.38M $43.94M $93.81M $94.85M $95.95M $96.93M $94.98M $94.53M $91.15M $84.04M $70.35M $51.47M $19.30M $11.51M $9.99M $9.83M $5.24M $478.00K $309.00K $390.00K
Goodwill $- $- $965.00K $965.00K $965.00K $965.00K $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Intangible Assets $120.00K $120.00K $9.51M $9.74M $9.98M $10.22M $- $120.00K $- $- $- $120.00K $120.00K $120.00K $120.00K $120.00K $120.00K $120.00K $120.00K $120.00K
Goodwill and Intangible Assets $120.00K $120.00K $10.47M $10.71M $10.95M $11.19M $- $120.00K $- $- $- $120.00K $120.00K $120.00K $120.00K $120.00K $120.00K $120.00K $120.00K $120.00K
Long Term Investments $- $- $900.00K $900.00K $244.00K $243.00K $242.00K $241.00K $- $- $- $240.00K $240.00K $240.00K $240.00K $- $- $- $- $-
Tax Assets $- $- $--0.00B $9.74M $-244.00K $-243.00K $- $-120.00K $- $- $- $-240.00K $-240.00K $-240.00K $-240.00K $- $- $- $- $-
Other Non-Current Assets $951.00K $961.00K $60.00K $-9.51M $1.05M $292.00K $143.00K $143.00K $360.00K $379.00K $379.00K $259.00K $271.00K $266.00K $245.00K $245.00K $239.00K $120.00K $107.00K $100.00K
Total Non-Current Assets $44.45M $45.02M $105.24M $106.69M $107.94M $108.41M $95.36M $94.91M $91.51M $84.42M $70.73M $51.85M $19.69M $11.90M $10.36M $10.19M $5.60M $718.00K $536.00K $610.00K
Other Assets $- $- $-0.00B $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Total Assets $94.99M $70.31M $135.34M $154.46M $139.28M $159.74M $179.09M $225.69M $242.65M $276.17M $223.72M $240.90M $214.77M $189.16M $183.52M $98.18M $67.62M $58.34M $33.93M $14.56M
Account Payables $3.94M $10.41M $6.65M $3.78M $7.80M $7.67M $8.02M $8.07M $4.56M $9.57M $9.40M $13.28M $7.96M $3.41M $2.86M $4.60M $1.77M $3.19M $1.41M $3.07M
Short Term Debt $275.00K $3.37M $3.10M $2.62M $868.00K $872.00K $876.00K $432.00K $1.01M $1.02M $794.00K $978.00K $1.17M $928.00K $772.00K $595.00K $1.07M $692.00K $512.00K $352.00K
Tax Payables $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Deferred Revenue $- $- $- $2.98M $- $- $- $3.27M $-504.00K $- $- $2.83M $- $- $- $2.17M $- $- $- $704.00K
Other Current Liabilities $10.97M $8.26M $10.73M $9.50M $9.07M $9.90M $4.18M $6.41M $7.78M $5.32M $5.16M $7.00M $2.90M $3.75M $2.40M $2.46M $1.54M $797.00K $740.00K $1.01M
Total Current Liabilities $15.18M $22.04M $20.48M $18.88M $17.73M $18.44M $13.07M $18.18M $13.34M $15.91M $15.35M $21.72M $12.03M $8.08M $6.03M $9.82M $4.38M $4.68M $2.66M $5.13M
Long Term Debt $5.60M $6.16M $6.72M $7.19M $716.00K $831.00K $588.00K $328.00K $382.00K $474.00K $405.00K $467.00K $530.00K $591.00K $577.00K $716.00K $671.00K $95.00K $25.00K $6.00K
Deferred Revenue Non-Current $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-80.00K $- $- $- $-
Deferred Tax Liabilities Non-Current $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-636.00K $- $- $- $-
Other Non-Current Liabilities $- $- $- $22.86M $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Total Non-Current Liabilities $5.60M $6.16M $6.72M $30.05M $716.00K $831.00K $588.00K $328.00K $382.00K $474.00K $405.00K $467.00K $530.00K $591.00K $577.00K $716.00K $671.00K $95.00K $25.00K $6.00K
Other Liabilities $- $- $- $- $- $- $- $- $- $31.50M $- $- $- $- $- $- $- $- $- $-
Total Liabilities $20.78M $28.20M $27.20M $48.93M $18.45M $19.27M $13.66M $18.51M $13.72M $47.88M $15.76M $22.18M $12.56M $8.67M $6.61M $10.54M $5.05M $4.77M $2.69M $5.14M
Preferred Stock $- $- $- $- $- $- $- $- $- $31.50M $- $359.82M $- $- $- $- $- $- $- $-
Common Stock $156.00K $10.00K $74.00K $59.00K $18.00K $11.00K $64.00K $76.00K $53.00K $32.00K $553.00K $496.00K $404.00K $346.00K $324.00K $206.00K $140.00K $105.00K $49.00K $9.00K
Retained Earnings $-708.59M $-694.37M $-615.60M $-600.66M $-573.34M $-545.36M $-516.99M $-470.04M $-438.36M $-409.38M $-386.24M $-359.82M $-330.27M $-311.74M $-288.19M $-267.53M $-250.51M $-238.52M $-224.34M $-217.07M
Accumulated Other Comprehensive Income Loss $-250.00K $-243.00K $-240.00K $-232.00K $-220.00K $-212.00K $-211.00K $-167.00K $-160.00K $-143.00K $-118.00K $-92.00K $-81.00K $-71.00K $-63.00K $-62.00K $-64.00K $-69.00K $-60.00K $-46.00K
Other Total Stockholders Equity $782.89M $736.71M $723.91M $706.36M $694.37M $686.02M $682.57M $677.31M $667.39M $637.77M $593.76M $578.13M $532.16M $491.96M $464.84M $355.04M $313.00M $292.06M $255.60M $226.52M
Total Stockholders Equity $74.21M $42.10M $108.14M $105.53M $120.83M $140.46M $165.43M $207.18M $228.92M $228.28M $207.96M $218.72M $202.22M $180.49M $176.92M $87.65M $62.57M $53.57M $31.25M $9.42M
Total Equity $74.21M $42.10M $108.14M $105.53M $120.83M $140.46M $165.43M $207.18M $228.92M $228.28M $207.96M $218.72M $202.22M $180.49M $176.92M $87.65M $62.57M $53.57M $31.25M $9.42M
Total Liabilities and Stockholders Equity $94.99M $70.31M $135.34M $154.46M $139.28M $159.74M $179.09M $225.69M $242.65M $276.17M $223.72M $240.90M $214.77M $189.16M $183.52M $98.18M $67.62M $58.34M $33.93M $14.56M
Minority Interest $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Total Liabilities and Total Equity $94.99M $70.31M $135.34M $154.46M $139.28M $159.74M $179.09M $225.69M $242.65M $276.17M $223.72M $240.90M $214.77M $189.16M $183.52M $98.18M $67.62M $58.34M $33.93M $14.56M
Total Investments $- $902.00K $900.00K $900.00K $244.00K $243.00K $242.00K $241.00K $- $- $- $240.00K $240.00K $240.00K $240.00K $- $- $- $- $-
Total Debt $5.87M $9.26M $9.82M $9.81M $1.15M $1.27M $1.03M $760.00K $886.00K $985.00K $802.00K $956.00K $1.11M $1.05M $963.00K $1.31M $1.21M $441.00K $281.00K $358.00K
Net Debt $-22.36M $5.10M $2.77M $-15.13M $-5.76M $-24.35M $-70.95M $-119.47M $-139.09M $-144.49M $-139.63M $-177.70M $-181.86M $-164.66M $-163.25M $-75.76M $-54.45M $-54.58M $-30.38M $-10.89M

Annual Cash Flow

Breakdown December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020 December 31, 2019
Net Income $-116.66M $-110.22M $-92.29M $-50.46M $-28.62M
Depreciation and Amortization $4.29M $1.25M $50.00K $27.00K $26.00K
Deferred Income Tax $- $-14.46M $- $- $154.00K
Stock Based Compensation $9.28M $10.91M $7.90M $2.88M $1.46M
Change in Working Capital $-35.00K $-2.00K $5.78M $-2.37M $452.00K
Accounts Receivables $- $- $- $- $-
Inventory $61.00K $- $- $- $-
Accounts Payables $-3.49M $-1.04M $3.53M $1.53M $1.66M
Other Working Capital $3.39M $1.04M $2.25M $-3.89M $-1.21M
Other Non Cash Items $1.12M $14.46M $3.00M $1.36M $-154.00K
Net Cash Provided by Operating Activities $-102.00M $-98.05M $-75.56M $-48.57M $-26.68M
Investments in Property Plant and Equipment $-7.89M $-48.15M $-35.31M $-8.56M $-17.00K
Acquisitions Net $-22.17M $- $- $- $-
Purchases of Investments $- $- $- $- $-
Sales Maturities of Investments $- $- $- $- $-
Other Investing Activities $999.00K $- $- $- $-17.00K
Net Cash Used for Investing Activities $-29.07M $-48.15M $-35.31M $-8.56M $-17.00K
Debt Repayment $8.94M $- $- $- $-
Common Stock Issued $18.94M $135.09M $212.39M $108.61M $5.84M
Common Stock Repurchased $-13.96M $-47.25M $- $- $-
Dividends Paid $- $-6.66M $- $-451.00K $-2.47M
Other Financing Activities $22.60M $40.00K $98.00K $14.95M $9.55M
Net Cash Used Provided by Financing Activities $36.52M $87.84M $212.49M $123.11M $12.92M
Effect of Forex Changes on Cash $-65.00K $-74.00K $-31.00K $-16.00K $-4.00K
Net Change in Cash $-94.62M $-58.43M $101.59M $65.96M $-13.79M
Cash at End of Period $25.85M $120.47M $178.90M $77.31M $11.35M
Cash at Beginning of Period $120.47M $178.90M $77.31M $11.35M $25.13M
Operating Cash Flow $-102.00M $-98.05M $-75.56M $-48.57M $-26.68M
Capital Expenditure $-7.89M $-48.15M $-35.31M $-8.56M $-17.00K
Free Cash Flow $-109.90M $-146.20M $-110.86M $-57.13M $-26.70M

Cash Flow Charts

Breakdown September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 September 30, 2021 June 30, 2021 March 31, 2021 December 31, 2020 September 30, 2020 June 30, 2020 March 31, 2020 December 31, 2019
Net Income $-14.21M $-78.78M $-14.94M $-27.32M $-27.98M $-28.36M $-33.01M $-31.68M $-28.98M $-23.14M $-26.42M $-29.55M $-18.53M $-23.55M $-20.65M $-17.02M $-11.99M $-14.18M $-7.27M $-8.71M
Depreciation and Amortization $510.00K $1.21M $1.21M $1.49M $1.22M $921.00K $893.00K $836.00K $252.00K $102.00K $63.00K $27.00K $10.00K $7.00K $6.00K $7.00K $8.00K $6.00K $6.00K $5.00K
Deferred Income Tax $- $- $- $-9.01M $- $-4.54M $-4.00M $-8.78M $- $-2.38M $- $-2.30M $- $- $- $2.37M $- $- $- $-452.00K
Stock Based Compensation $1.04M $1.15M $1.69M $2.04M $2.08M $2.36M $2.79M $2.72M $2.77M $2.81M $2.62M $2.30M $2.30M $2.09M $1.21M $871.00K $912.00K $733.00K $360.00K $359.00K
Change in Working Capital $-5.89M $4.82M $1.17M $372.37K $1.49M $1.70M $-3.59M $5.83M $2.43M $-946.00K $-7.31M $4.79M $3.27M $-651.00K $-1.62M $2.23M $-4.21M $2.04M $-2.42M $1.63M
Accounts Receivables $-1.64M $- $- $-61.00K $-1.56M $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Inventory $-385.92K $1.16M $1.29M $61.00K $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Accounts Payables $-6.25M $3.73M $2.98M $-3.99M $1.02M $-1.15M $575.00K $3.03M $-2.52M $1.55M $-3.11M $156.00K $4.56M $548.00K $-1.74M $2.83M $-1.42M $1.78M $-1.66M $1.95M
Other Working Capital $2.39M $-64.00K $-3.10M $4.36M $474.00K $2.85M $-4.17M $2.79M $3.00K $-2.50M $-4.20M $4.63M $-1.29M $-1.20M $116.00K $-600.00K $-2.80M $259.00K $-757.00K $-319.00K
Other Non Cash Items $-250.13K $61.68M $-6.86M $10.74M $-196.00K $4.54M $4.00M $8.78M $-2.45M $2.38M $5.86M $2.30M $-1.77M $3.00M $2.96M $-2.37M $-1.43M $1.36M $-1.70M $452.00K
Net Cash Provided by Operating Activities $-18.80M $-9.92M $-17.57M $-21.69M $-23.39M $-23.37M $-32.91M $-22.30M $-23.54M $-21.17M $-31.05M $-22.45M $-12.95M $-19.11M $-21.06M $-13.91M $-15.29M $-10.04M $-9.33M $-6.71M
Investments in Property Plant and Equipment $-10.77K $1.77K $-108.00K $-355.65K $-1.81M $-1.84M $-3.80M $-4.67M $-8.82M $-14.44M $-20.22M $-25.62M $-7.75M $-1.43M $-505.00K $-4.53M $-4.02M $-14.00K $- $-5.00K
Acquisitions Net $- $- $- $257.05K $794.02K $-22.50M $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Purchases of Investments $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Sales Maturities of Investments $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Other Investing Activities $1.77K $- $- $7.00K $197.98K $324.96K $- $- $- $- $- $25.62M $- $- $- $- $- $- $- $-17.00K
Net Cash Used for Investing Activities $-9.00K $1.77K $-108.00K $-98.60K $-821.00K $-24.02M $-3.80M $-4.67M $-8.82M $-14.44M $-20.22M $-25.62M $-7.75M $-1.43M $-505.00K $-4.53M $-4.02M $-14.00K $- $-5.00K
Debt Repayment $-705.00K $-705.00K $-235.00K $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Common Stock Issued $43.61M $10.73M $23.00K $9.20M $6.27M $1.03M $2.44M $9.63M $26.88M $44.93M $13.02M $43.77M $37.89M $22.05M $108.68M $39.86M $17.65M $34.42M $16.68M $965.00K
Common Stock Repurchased $- $- $- $- $- $- $-13.96M $- $- $- $- $- $- $- $- $- $- $- $- $-
Dividends Paid $- $- $- $- $- $- $- $-4.25M $- $- $- $- $- $- $- $-451.00K $- $- $-1.26M $-2.47M
Other Financing Activities $4.00K $-3.11M $23.00K $31.51M $- $- $29.00K $9.08M $-36.12M $27.25M $40.00K $- $68.00K $- $30.00K $451.00K $2.42M $- $13.34M $9.45M
Net Cash Used Provided by Financing Activities $42.91M $6.91M $-212.00K $41.29M $6.27M $1.03M $-11.50M $7.23M $-4.62M $72.18M $13.06M $43.77M $37.96M $22.05M $108.71M $39.86M $20.07M $34.42M $28.76M $7.95M
Effect of Forex Changes on Cash $-17.00K $1.00K $-4.00K $-10.00K $-12.00K $- $-43.00K $-5.00K $-20.00K $-24.00K $-25.00K $-10.00K $-13.00K $-7.00K $-1.00K $16.00K $7.00K $-8.00K $-15.00K $-1.00K
Net Change in Cash $24.08M $-2.89M $-17.90M $18.03M $-17.94M $-46.36M $-48.25M $-19.75M $-37.00M $36.54M $-38.23M $-4.31M $17.25M $1.50M $87.15M $21.41M $775.00K $24.36M $19.42M $1.23M
Cash at End of Period $29.14M $4.16M $7.05M $24.95M $7.92M $25.86M $72.22M $120.47M $140.22M $177.22M $140.68M $178.90M $183.21M $165.96M $164.45M $77.31M $55.90M $55.12M $30.77M $11.35M
Cash at Beginning of Period $5.06M $7.05M $24.95M $6.91M $25.86M $72.22M $120.47M $140.22M $177.22M $140.68M $178.90M $183.21M $165.96M $164.45M $77.31M $55.90M $55.12M $30.77M $11.35M $10.12M
Operating Cash Flow $-18.80M $-9.47M $-17.57M $-21.69M $-23.39M $-23.37M $-32.91M $-22.30M $-23.54M $-21.17M $-31.05M $-22.45M $-12.95M $-19.11M $-21.06M $-13.91M $-15.29M $-10.04M $-9.33M $-6.71M
Capital Expenditure $-9.00K $1.77K $-108.00K $-355.65K $-1.81M $-1.84M $-3.80M $-4.67M $-8.82M $-14.44M $-20.22M $-25.62M $-7.75M $-1.43M $-505.00K $-4.53M $-4.02M $-14.00K $- $-5.00K
Free Cash Flow $-18.81M $-9.92M $-17.68M $-22.04M $-25.20M $-25.21M $-36.71M $-26.97M $-32.35M $-35.61M $-51.26M $-48.07M $-20.70M $-20.54M $-21.56M $-18.45M $-19.30M $-10.05M $-9.33M $-6.72M


Tonix Pharmaceuticals Holding Stock Forecast

Analyst ratings, price targets, and earnings estimates for TNXP.

TNXP Analyst Ratings

Strong Buy

Buy
4
Hold
1
Sell
0

Based on 5 analysts in the past 3 months

Recent Price Targets
Recommendation Trends
Analyst Estimates
Revenue Estimates
High $18.14M
Average $13.35M
Low $8.55M
2 analysts
Net Income Estimates
High $-2.25M
Average $-32.98M
Low $-63.71M
2 analysts
EPS Estimates
High $-4.23
Average $-62.00
Low $-119.65
1 analysts
Revenue Estimates
High $40.56M
Average $30.60M
Low $20.63M
1 analysts
Net Income Estimates
High $-8.29M
Average $-14.37M
Low $-20.46M
1 analysts
EPS Estimates
High $-15.57
Average $-27.00
Low $-38.42
1 analysts
Revenue Estimates
High $503.25M
Average $379.69M
Low $256.00M
1 analysts
Net Income Estimates
High $2.93B
Average $2.06B
Low $1.19B
1 analysts
EPS Estimates
High $5509.97
Average $3872.00
Low $2232.24
1 analysts
Revenue Estimates
High $872.05M
Average $657.95M
Low $443.61M
1 analysts
Net Income Estimates
High $1.83M
Average $1.28M
Low $739.82K
1 analysts
EPS Estimates
High $3.43
Average $2.41
Low $1.39
1 analysts
Latest Price Target Updates
Date Analyst Firm Price Target Price When Posted Upside

Tonix Pharmaceuticals Holding Dividends

Explore Tonix Pharmaceuticals Holding's dividend history, including dividend yield, payout ratio, and historical payments.

Tonix Pharmaceuticals Holding does not currently pay a dividend.

Peers: Biotechnology

This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.

Company Market Cap Price EPS P/E Ratio P/B Ratio
SONN Logo
Sonnet BioTherapeutics Holdings, Inc.
SONN
$4.94M $1.62 $-11.35 $-0.59 $-9.02
ONTX Logo
Onconova Therapeutics, Inc.
ONTX
$20.90M $1.00 $-0.90 $-21.88 $38.84
PALI Logo
Palisade Bio, Inc.
PALI
$3.52M $1.27 $-26.97 $-0.33 $0.36
IBIO Logo
iBio, Inc.
IBIO
$35.54M $3.62 $-6.50 $-0.31 $0.36
JAGX Logo
Jaguar Health, Inc.
JAGX
$9.92M $0.84 $-107.42 $-0.03 $0.23
ACST Logo
Acasti Pharma Inc.
ACST
$34.17M $3.37 $-1.35 $-2.56 $0.53
DFFN Logo
Diffusion Pharmaceuticals Inc.
DFFN
$8.98M $4.40 $-0.82 $-9.35 $2.75
VXRT Logo
Vaxart, Inc.
VXRT
$162.72M $0.72 $-0.57 $-1.01 $1.44
VBIV Logo
VBI Vaccines Inc.
VBIV
$1.87M $0.07 $-5.96 $-0.10 $1.22
DRUG Logo
Bright Minds Biosciences Inc.
DRUG
$283.75M $40.60 $0.00 $0.00 $0.00
VRAX Logo
Virax Biolabs Group Limited
VRAX
$8.42M $1.94 $-3.36 $-0.22 $0.27
NVAX Logo
Novavax, Inc.
NVAX
$1.33B $8.31 $-5.41 $-0.89 $-0.67
INO Logo
Inovio Pharmaceuticals, Inc.
INO
$71.12M $1.97 $-6.09 $-1.00 $1.16
ENVB Logo
Enveric Biosciences, Inc.
ENVB
$3.61M $1.65 $-0.01 $-2434.79 $21.52
CWBR Logo
CohBar, Inc.
CWBR
$1.19M $0.41 $-4.13 $-0.41 $0.32
Current Reports (8-K)
Ownership